

Antiabsence effects of safranal in acute experimental seizure models: EEG and autoradiography

Sadeghnia, H.R.^{af}, Cortez, M.A.^{cdef}, Liu, D.^f, Hosseinzadeh, H.^b, Carter Snead, O.^{cdef}

^a Department of Pharmacology, Faculty of Medicine, **Mashhad University of Medical Sciences, Mashhad, Iran**

^b Pharmaceutical Research Center, Faculty of Pharmacy, **Mashhad University of Medical Sciences, Mashhad, Iran**

^c Department of Pediatrics, Faculty of Medicine, **University of Toronto, University Avenue, Toronto, ON, Canada**

^d Hospital for Sick Children, Toronto, ON, Canada

^e Division of Neurology, Hospital for Sick Children, Toronto, ON, Canada

^f Neuroscience and Mental Health Program Research Institute, Hospital for Sick Children, Toronto, ON, Canada

[View references \(12\)](#)

Abstract

PURPOSE. We examined the effect of safranal, a constituent of *Crocus sativus*, in acute experimental animal models of generalized absence seizures. **METHODS.** the effect of acute systemic administration of safranal on latency to seizure onset as well as spike and wave discharges (SWD) duration following pharmacologically induced absence seizures was investigated in wildtype mice. We further characterized its effects on the GABAergic system through the regional modification of [³H] flunitrazepam, a benzodiazepine agonist binding site and [³H] CGP52786A, a GABA_B receptor antagonist binding site in mouse brain. **RESULTS.** The systemic administration of safranal resulted in a significant and dose-dependent attenuation in experimental absence seizures elicited by either γ -butyrolactone (GBL), baclofen (BAC) or low doses of GABA_A receptor antagonists; pentylenetetrazole (PTZ), picrotoxin (PTX) and bicuculline (BMC). After a single intraperitoneal administration of safranal (100 mg/kg), no changes in baseline electrocorticographic (ECoG) recording were observed, however, a significant decrease in [³H] flunitrazepam binding was seen in the cortex (33.16%, p<0.001), hippocampus (27.36%, p<0.001) and thalamus (19.91%, p<0.001) of mouse brain, while the [³H] CGP52786A binding did not show any modification in the same brain regions. **CONCLUSION.** These data indicate that there is an antiabsence seizure property in safranal and its effect may be due to modifications on the benzodiazepine binding sites of the GABA_A receptor complex.

Reaxys Database Information

Indexed Keywords

EMTREE drug terms: ϵ aminobutyric acid A receptor; cyclohexene derivative; safranal; terpene; unclassified drug

EMTREE medical terms: absence; animal; article; autoradiography; binding site; brain; C⁵⁷BL mouse; chemistry; *Crocus*; disease model; dose response; drug effect; electroencephalography; intraperitoneal drug administration; isolation and purification; male; metabolism; methodology; mouse; pathophysiology

MeSH: Animals; Autoradiography; Binding Sites; Brain; *Crocus*; Cyclohexenes; Disease Models, Animal; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy, Absence; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C⁵⁷BL; Receptors, GABA-A; Terpenes

Medline is the source for the MeSH terms of this document.

Chemicals and CAS Registry Numbers: Cyclohexenes; Receptors, GABA-A; Terpenes; safranal, 111-26-7

ISSN: 1542-1826 **CODEN:** JPPSFS **Source Type:** Journal **Original language:** English

Document Type: Article